

Document downloaded from:

<http://hdl.handle.net/10251/137418>

This paper must be cited as:

Shani-Levi, C.; Alvito, P.; Andrés Grau, AM.; Assunção, R.; Barbera, R.; Blanquet-Diot, S.; Bourlieu, C.... (2017). Extending in vitro digestion models to specific human populations: Perspectives, practical tools and bio-relevant information. *Trends in Food Science & Technology*. 60:52-63. <https://doi.org/10.1016/j.tifs.2016.10.017>



The final publication is available at

<https://doi.org/10.1016/j.tifs.2016.10.017>

Copyright Elsevier

Additional Information

1 *EXTENDING IN VITRO DIGESTION MODELS TO SPECIFIC HUMAN*
2 *POPULATIONS: PERSPECTIVES, PRACTICAL TOOLS AND BIO-RELEVANT*
3 *INFORMATION*

4 Carmit Shani Levi^a, Paula Alvito^{bc}, Ana Andrés^d, Ricardo Assunção^{bc}, Reyes Barberá^e,
5 Stéphanie Blanquet-Diot^f, Claire Bourlieu^g, André Brodkorbⁱ, Antonio Cilla^e, Amélie
6 Deglaire^h, Sylvain Denis^f, Didier Dupont^h, Ana Heredia^d, Sibel Karakaya^j, Concetta
7 Valeria Lucia Giosafatto^k, Loredana Mariniello^k, Carla Martins^{bc}, Olivia Ménard^h, Sedef
8 Nehir El^j, Gerd Elizabeth Vegarud^l, Ellen Ulleberg^l, and Uri Lesmes^{a*}
9

10 ^a*Department of Biotechnology and Food Engineering, Technion – Israel Institute of Technology, Haifa,*
11 *Israel*

12 ^b*Food and Nutrition Department, National Institute of Health, Lisbon, Portugal*

13 ^c*CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Portugal*

14 ^d*Institute of Food Engineering for Development, Universitat Politècnica de València, Valencia, Spain*

15 ^e*Faculty of Pharmacy, University of Valencia, Valencia, Spain*

16 ^f*Engineering and Development of Food and Drug, University of Auvergne, Clermont-Ferrand, France.*

17 ^g*IATE 1208, INRA, CIRAD, SupAgro, Montpellier, France*

18 ^h*STLO Agrocampus Ouest, INRA, Rennes, France*

19 ⁱ*Teagasc Food Research Centre, Cork, Ireland*

20 ^j*Food Engineering Department, Ege University, İzmir, Turkey*

21 ^k*Department of Chemical Sciences, University of Naples Federico II, Naples, Italy*

22 ^l*Norwegian university of Life Sciences, As, Norway*

23

24 * Corresponding Author: Assistant Prof. Uri Lesmes
25 Laboratory of Chemistry of Foods and Bioactives
26 Department of Biotechnology and Food Engineering,
27 Technion – Israel Institute of Technology, Haifa 32000,
28 Israel
29 Tel. 972-77-8871869; Fax.972-4-8293399
30 Email: lesmesu@bfe.technion.ac.il
31

32 Submitted to: Trends in Food Science and Technology, **Special issue**

33 Revision date: October 2016

34

35 **Abstract**

36 **Background.** *In vitro* digestion models show great promise in facilitating the rationale
37 design of foods. This paper provides a look into the current state of the art and outlines
38 possible future paths for developments of digestion models recreating the diverse
39 physiological conditions of specific groups of the human population.

40 **Scope and Approach.** Based on a collective effort of experts, this paper outlines
41 considerations and parameters needed for development of new *in vitro* digestion models,
42 e.g. gastric pH, enzymatic activities, gastric emptying rate and more. These and other
43 parameters are detrimental to the adequate development of *in vitro* models that enable
44 deeper insight into matters of food luminal breakdown as well as nutrient and
45 nutraceutical bioaccessibility. Subsequently, we present an overview of some new and
46 emerging *in vitro* digestion models mirroring the gastro-intestinal conditions of infants,
47 the elderly and patients of cystic fibrosis or gastric bypass surgery.

48 **Key Findings and Conclusions.** This paper calls for synchronization, harmonization and
49 validation of potential developments in *in vitro* digestion models that would greatly
50 facilitate manufacturing of foods tailored or even personalized, to a certain extent, to
51 various strata of the human population.

52 **Key words:** Food digestion, *In vitro* digestion, gastric, infants, elderly, Gastro-Intestinal
53 disorders

54 **Abbreviations:** CF-Cystic Fibrosis; EFFoST-European Federation of Food Science and
55 Technology; GBP-Gastric Bypass; GI-Gastrointestinal; GIT-Gastrointestinal tract; IBD-
56 inflammatory bowel disease; IVD- In vitro digestion; PTL:Pancreatic Triglyceride
57 Lipase; SG: Sleeve Gastrectomy

58 **1. Introduction**

59 **1.1 *In vitro* models for food research**

60 *In vitro* digestion (IVD) modelling is a vivid field of research that shows great promise in
61 facilitating the development of foods and oral formulations based on better understanding
62 of their digestive fate in the stomach and small intestine in as well as downstream
63 ramifications to the gut microbiome(Bornhorst, Gouseti, Wickham, & Bakalis, 2016;
64 Guerra, et al., 2012; Hur, Lim, Decker, & McClements, 2011; Payne, Zihler, Chassard, &
65 Lacroix, 2012). Although human or *in vivo* animal studies are still considered a “gold
66 standard” for tackling issues of bioaccessibility, absorption, bioavailability, metabolism
67 and excretion, IVD methods have the advantage of being more rapid, less labor intensive
68 and having significantly less bioethical restrictions. In fact, various IVD models have
69 been increasingly applied to assess the digestive fate and potential toxicity of ingested
70 natural and engineered nano-materials(Lefebvre, et al., 2015). This has led to great
71 variability in scientific efforts, including some contradicting studies, and stimulated the
72 recent effort of the INFOGEST network of scientists to develop a consensus harmonized
73 static *in vitro* digestion model based on physiologically relevant conditions gathered from
74 humans(Minekus, et al., 2014). This harmonized protocol was validated in a wide inter-
75 laboratory trial(Egger, et al., 2016) and is currently pending on-going efforts to correlate
76 findings of protein digestibility with an *in vivo* trial in pigs and biochemical assays with
77 human aspirates (yet to be published). However, these and other numerous scientific
78 publications focus on IVD systems designed for evaluating the digestive fate of foods and
79 oral formulations in the adult alimentary canal.

80 During a dedicated workshop held by the European Federation of Food Science and
81 Technology (EFFoST) in Athens on November 2015, we found that current physiological
82 literature offers professionals additional opportunities to recreate the unique and specific
83 gastro-intestinal (GI) functions of other human populations, such as infants, the elderly
84 and more. Such intriguing possibilities would open new opportunities to study and
85 develop foods and oral formulations better tailored to the needs of such specific
86 populations. Based on the pooled and accumulated experience of the INFOGEST
87 network, it was decided to help a systematic and responsible orchestration of relevant
88 global efforts, maximize synergisms between researchers and harmonize efforts to
89 develop new IVD models. Thus, this paper provides a look into the current state of the art
90 and paves possible future paths for developments, all with the aim of ensuring adequate
91 and fruitful endeavors and outputs to the food and health community.

92 1.2 Current status of adult *in vitro* digestion (IVD) models

93 *In vitro* digestion models were initially developed to serve as research tools to
94 characterize and clarify the structural and biochemical changes of food components under
95 physiological conditions, caused by alimentary enzymes, GI motility and by the colonic
96 microbiota. In principle, IVD models of the upper GI need to overcome the shortcomings
97 of *in vivo* trials (*i.e.* ethical constraints, low throughput, control over subjects and
98 reproducibility) and account for the most bio-relevant anatomical and physiological
99 considerations mirroring the mouth, stomach, small and large intestine lumen and gut
100 lining. In fact and in spite of their limitations, IVD models are particularly suited for
101 investigating the luminal physiochemical changes in food, matters of bioaccessibility and
102 some aspects of bioavailability.

103 Historically, efforts to develop IVD models began in the early 1990's with pioneering
104 works to develop reliable, robust, reproducible and bio-relevant tools like the multi-
105 compartmental GI model developed by TNO in the Netherlands(Minekus, Marteau,
106 Havenaar, & Huisintveld, 1995) or the three stage continuous fermentation systems
107 recreating the human colon(Macfarlane, Macfarlane, & Gibson, 1998; Molly, Woestyne,
108 & Verstraete, 1993). Since, the field has boomed with numerous IVD models, ranging
109 from simple static mono-compartmental models to computer-controlled multi-
110 compartmental dynamic IVD models, as reviewed by others (Glahn, Wien, VanCampen,
111 & Miller, 1996; Guerra, et al., 2012; Hur, et al., 2011; McClements & Li, 2010; Payne, et
112 al., 2012; Yoo & Chen, 2006). Recent studies even raised the possibility of using human
113 GI aspirates in IVD models (Ulleberg, et al., 2011) or coupling IVD models with human
114 cell cultures of Caco-2 epithelial cells or Caco-2 co-cultures with HT-29 mucus
115 producing cells (Emmanuelle Deat, et al., 2009; E. Deat, et al., 2009; Vors, et al., 2012).
116 Yet, the low accessibility and stability of human aspirates and the complexity of coupling
117 IVD research with cell cultures, challenge the wide spread use of highly bio-relevant
118 alternatives over simple protocols currently used in IVD models. Further, *in vitro* cell
119 culture systems have been coupled to some IVD models to enable investigating questions
120 of cellular uptake and brush border enzymatic breakdown, which better elucidate the
121 bioavailability of specific substances(Emmanuelle Deat, et al., 2009; E. Deat, et al., 2009;
122 Manione, et al., 2015; Vors, et al., 2012).

123 Concomitantly, various efforts reported to develop and apply sophisticated IVD models
124 that are intended to be more realistic, encompassing various aspects of digestion
125 dynamics (e.g. physiological acid secretion and gastric emptying), mass transport

126 phenomena (*i.e.* absorption and diffusion) and rheological aspects (*i.e.* mixing) (Blanquet,
127 et al., 2004; Dekkers, Kolodziejczyk, Acquistapace, Engmann, & Wooster, 2016; Kong
128 & Singh, 2010a; Levi & Lesmes, 2014; Mercuri, Lo Curto, Wickham, Craig, & Barker,
129 2008; Shani-Levi, Levi-Tal, & Lesmes, 2013; Tharakan, Norton, Fryer, & Bakalis, 2010;
130 Yoo & Chen, 2006). To date, both advanced and simple IVD models have be used to
131 investigate a variety of systems. Examples include investigations of simple high purity
132 protein solutions, multi-component model systems like emulsions and even more real
133 foods, like dairy gels and pasta. These and other investigations have significantly
134 advanced our understanding of the interplay between food ingredients, food products and
135 the alimentary canal of healthy adults. Such insights include not just understanding of
136 food breakdown but also its impact on gastro-intestinal functions, e.g. gastric emptying
137 and intestinal motility, as detailed by others (Grundy, et al., 2016; Houghton, Hickson, &
138 Read, 1987; Meyer, Elashoff, & Lake, 1999; Sarosiek, et al., 2010).

139 **Identified research needs.** Despite the various hectic activity in the field of
140 understanding food's digestion in adults, there is still much room for further
141 advancements and breaching of current gaps in knowledge and capabilities. The various
142 discussions held during the Athens workshop identified that amongst future
143 advancements in the field, research should include efforts: [I] To improve the bio-
144 relevance of luminal composition and dynamics (e.g. pH profiles and use of gastric
145 lipases); [II] To validate and/or correlate IVD data with *in vivo* findings; [III] To recreate
146 the 3D micro-architecture of the intestinal lining and mucosa through co-cultures (e.g.
147 Caco-2 and HT29 cell lines, grown on various scaffolds); and [IV] To develop predictive

148 *in silico* models. All of these topics were enthusiastically discussed in separate work
149 groups during the workshop and are expected to bring up further scientific publications.

150 1.3 Rationale and approach for extending IVD models

151 Advancements in the field of food science and technology need to address numerous
152 challenges that humanity is and will be facing in the 21 century (Floros, et al., 2010).
153 These challenges will include feeding the growing and ageing world population, better
154 and sustainable use of natural resources as well as improving our ability to exploit foods'
155 potential to prevent diseases and maintain health promote wellness. In this respect,
156 personalized or tailored nutrition seem highly promising and challenging strategies
157 (Joost, et al., 2007; Qi, 2014; Zeevi, et al., 2015). Such endeavors will require bridging
158 manufacturing capabilities and product engineering to meet the specific needs of the
159 consumer. Based on the demonstrated success in the field of infant formula development,
160 IVD models harbor great potential to facilitate relevant developments of foods tailored to
161 the specific GI capabilities of specific human starta such as elderly people, pregnant
162 women, patients of various Inflammatory Bowel Diseases (IBD) and even diabetics.
163 Thus, this paper outlines the considerations and parameters needed for development of
164 new IVD models as well as an overview of some of the new and emerging IVD models
165 and the relevant physiological information, all with the aim of stimulating adequate and
166 fruitful endeavors and outputs to the food and health community. Adapting the consensus
167 INFOGEST protocol scheme, a basic static model is suggested to comprise of an oral,
168 gastric and intestinal phase (Minekus, et al., 2014). Each phase should address the
169 composition of the relevant simulated fluid (ionic and enzymatic composition), the time
170 of processing and the nature of the bolus/chyme (liquid, semi-solid or solid and dilution

171 ratio with the bodily secretions). The selection of the quantitative aspects for the
172 operational parameters should rely on information gathered from the most relevant
173 human studies with good statistical power (*i.e.* avoiding studies with less than 10 subjects
174 as a rule of thumb). In circumstances where no human data can be found, developers
175 should either make their best effort to rationally approximate the values or attempt to
176 determine them directly as a part of a human trial. Thus, any new IVD model should
177 clearly define its parameters, justify their selection and support it with relevant
178 references.

179 **2. Practical considerations for developing IVD models**

180 Human GI physiology is a complicated semi-continuous set of bioreactors that are
181 intertwined with the hematological, hormonal and nervous systems and change during
182 life(L R Johnson, 2007; Remond, et al., 2015; Tortora & Derrickson, 2011). This highly
183 complex nature of the GI limits the ability to recreate its entire functions in an *in vitro*
184 model. However, many aspects of luminal digestion can be mirrored in IVD models using
185 reliable and detailed information on the digestive system that can be found in the
186 scientific literature. Therefore, it is imperative to understand the limitations of each
187 model and ensure they do not collide with the research hypotheses. To this end, it is also
188 imperative to be aware of and address the key anatomical and physiological parameters of
189 the relevant GI organs.

190 The process of food digestion is an orchestrated series of bioprocessing operations that
191 involve the breakdown of food, the release of nutrients, their uptake or downstream
192 fermentation before their ultimate removal from the body through defecation. During
193 digestion in the upper GI, food structure is broken down in the mouth, stomach and small

194 intestine through complex reactions and interactions involving chemical and mechanical
195 processes (Ferrua & Singh, 2010; L R Johnson, 2007; Sensoy, 2014). Therefore, the
196 following section discuss the most critical physiological parameters that are essential for
197 *in vitro* digestion models.

198 2.1. Oral phase

199 Oral processing involves mastication and mechanical breakdown of food into a soft mass,
200 termed bolus which is a mixture of processed food and saliva(DeSesso & Jacobson,
201 2001). This short phase is detrimental to the sensorial perception of food and can be
202 viewed as a coarse mechanical processing step with little chemical changes(Aken,
203 Vingerhoeds, & Wijk, 2011; van Vliet, van Aken, de Jongh, & Hamer, 2009). This first
204 step of digestion involves mixing food with salivary fluid that contains about 99% water
205 in addition to various electrolytes and proteins, including enzymes such as amylase(Aps
206 & Martens, 2005; Rantonen, 2003). Saliva is continuously secreted into the oral cavity by
207 parasympathetic control. While resting, the flow rate is about 0.5 ml/min; but upon
208 stimulation, the secretion increases 3 to 4- fold with maximal flow rates of 10
209 ml/min(AC, 1991b). Healthy adults will produce 500–1500 ml saliva per day(Aps &
210 Martens, 2005). Salivary fluid composition depends on the flow rate: at higher flow rates,
211 sodium, calcium, chloride, bicarbonate, amylase increase while phosphate and mucin
212 concentrations decrease, and the potassium concentrations show little change. Salivary
213 pH values also fluctuate between fasted to fed state with values of 6.2-7.4 to 7.4-7.6,
214 respectively(C. H. M. Versantvoort, Van de Kamp, E. and Rompelberg, C.J.M., 2004).
215 The key salivary enzyme is α -amylase that hydrolyzes starch and related α -(1,4)-linked
216 polysaccharides(Nagler & Hershkovich, 2005; Shern, Fox, & Li, 1993). Mucin is also an

217 important component of saliva with studies indicating it to induce emulsion
218 flocculation(Sarkar, Goh, & Singh, 2009, 2010; Singh & Ye, 2013; Vingerhoeds, Silletti,
219 de Groot, Schipper, & van Aken, 2009). Yet, commercial mucins are partially hydrolyzed
220 mixtures of mammalian mucins which limit their bio-relevance when applied in IVD
221 models. In addition, there is some debate on the possible existence and activity of lingual
222 lipase with a report indicating lingual lipase is active between pH 2-6.4, indicating that
223 this enzyme is active from the mouth to the small intestine(Hamosh, 1994).

224 2.2 Gastric phase

225 Following bolus formation in the oral phase, the stomach further processes the bolus into
226 a semi-solid chyme within four distinct regions: cardiac, fundic, body and the pyloric
227 regions (Ferrua & Singh, 2010; Kong & Singh, 2010b). Gastric juice comprises of
228 hydrochloric acid, enzymes (pepsin and gastric lipase), various electrolytes, mucus,
229 intrinsic factor and hormones with approximately 2 L of gastric juice secreted daily and
230 0.7 L secreted after a typical meal(Kopf-Bolanz, et al., 2012; Seeley, Stephens, & Tate,
231 1992). Parietal cells lining the stomach wall are responsible for the secretion of
232 hydrochloric acid into the gastric lumen and bicarbonate into the bloodstream. The
233 activity of these cells is responsible for the unique pH of the stomach which dynamically
234 changes during digestion from 1.5-2.0 in the fasted state to 3.0-7.0 in the fed state.
235 Gastric acidity induces protein denaturation and precipitation, hydrolytic reactions (e.g.
236 breakdown of starch) and significantly reduces bacterial counts in the gastric lumen. The
237 post-prandial pH rise in the stomach is attributed to the buffering capacity of the ingested
238 food and the Parietal cells generate a pH gradient that over the course of time reverts
239 luminal pH back to the fasted state values. The pH profiles depend on age and clinical

240 conditions of the consumer (**Table 1**) and can have various ramifications to the properties
241 of ingested food systems, such as emulsions and gels(Dekkers, et al., 2016; Shani-Levi, et
242 al., 2013). Gastric lipolysis and proteolysis are tightly linked(AC, 1991b; Sams, Paume,
243 Giallo, & Carriere, 2016). The key gastric proteolytic enzyme, pepsin, is activated from
244 its precursor pepsinogen (secreted by chief cells) via acid hydrolysis. The activated
245 enzyme, which is also equated with commercial porcine pepsin, has a wide range of
246 activity with optimal activity at pH 2 and inactivate just above pH 6.5(Johnston, Dettmar,
247 Bishwokarma, Lively, & Koufman, 2007). Pepsin is a non-specific protease and therefore
248 hydrolyses itself (a reaction termed auto-pepsinolysis) and other enzymes present in the
249 lumen. Another gastric enzyme is gastric lipase which is also activated by the acidic
250 environment in the stomach(Sams, et al., 2016). Gastric lipase presents *sn*-3
251 regiospecificity thus it hydrolyses triglycerides into *sn*-1,2diglycerides and one free fatty
252 acid, pancreatic triglyceride lipase colipase dependent which is *sn*-1,3 regioselective
253 lipase (Miled, et al., 2000). However, commercial gastric lipase is hard to find and is
254 currently neglected in many IVD models, thought it initiates lipolysis and release free
255 fatty acids which activate pancreatic triglyceride lipase.

256 The pyloric sphincter controls gastric emptying into the small intestine and is affected by
257 three major factors: volume of the meal, its osmotic pressure and caloric content.
258 Approximately 2 kcal/per minute are delivered through the pylorus to the
259 duodenum(Campbell, 2015; Sams, et al., 2016). Furthermore, gastric emptying has been
260 well described by the Elashoff equation (Elashoff, Reedy, & Meyer, 1982).

261

262 2.3 Small intestinal phase

263 Gastric chyme is gradually emptied into the small intestine, where most of the chemical
264 breakdown and absorption occur mediated by auxiliary secretions of the liver, gall
265 bladder, pancreas and intestinal epithelia. Chyme entering from the stomach to the small
266 intestine are neutralized using bicarbonate and the pH increases from 2 to 6.2 in the
267 duodenum, which is the first segment of the small intestine(Kalantzi, et al., 2006). The
268 main degradation of food starts in the duodenum into which about 1.2-1.5 L of pancreatic
269 juice is secreted daily(L.R. Johnson, 2007). The jejunum and ileum are the later sections
270 of the small intestine where digestion and absorption are completed before indigested
271 fractions are pushed into the colon. Due to the anatomical complexity of the small
272 intestine one cannot easily find data on food digestion in these segments. The pancreatic
273 juice contains a mixture of enzymes, proenzymes, protease inhibitors, sodium bicarbonate
274 and other electrolytes that are secreted in parallel and gradually over the course of 3-4
275 hours, depending on the meal ingested. The pancreatic secretions contain a variety of
276 enzymes in their pro-enzyme forms and include protrypsin, prochymotrypsin, proelastase,
277 procarboxypeptidases, pancreatic lipase and α -amylase in addition to ribonuclease and
278 deoxyribonuclease(Boivin, Lanspa, Zinsmeister, Go, & Dimagno, 1990; Keller & Layer,
279 2005). Currently, IVD models make use of ill-defined mixtures of pancreatin or concoct
280 enzyme mixtures mainly containing trypsin and α -chymotrypsin. Every day, the human
281 liver produces about 0.6-1.0 L of bile, which are stored in the gallbladder(Seeley, et al.,
282 1992). Bile acids are steroid acids composed mainly from taurocholic acid, glycocholic
283 acid, taurochenodeoxycholic acid and glycochenodeoxycholic acid which are equal in
284 concentration(Hofmann, 1999). In addition to enzymes delivered into the lumen,

285 enzymes located in the epithelial brush border contribute to the further digestion of food.
286 The brush border enzymes include glycosidases (dextrinase, glucoamylase), peptidases
287 (aminopeptidase, carboxypeptidase, dipeptidase) and phosphatases(Holmes & Lobley,
288 1989). Altogether, the functions of the auxiliary organs in the fasted and fed conditions
289 are stimuli responsive and are mainly affected by the composition of the ingested meal
290 and the physical state of the consumer. Unfortunately, a wide range of enzyme outputs
291 and activities (units) are reported due to different focus of the studies; type of diet
292 (calories), specific nutrient (lipid, carbohydrate, protein or minerals) or non-nutrients
293 (pharmaceuticals, drugs etc.) and physical properties of the meal(Armand, et al., 1996;
294 O'Keefe, et al., 2003). Further, there are inconsistencies in data on the pancreatic enzyme
295 activities due to the differences in biochemical assays used to characterize these
296 secretions: ranging from use of natural or synthetic standards such as casein, BAEE,
297 TAME, BTEE, measurement modes (potentiometric, colorimetric, spectrophotometric),
298 calculation methods up to the definition of enzymatic units of activity. Examples for
299 values found in literature are summarized in **Table 1**. Mechanically, the small intestine
300 has a segmented nature of pushing chyme further down the GI and this segmentation
301 motion was recently shown to be critical for luminal mixing and mass transfer (Tharakan,
302 et al., 2010).

303 As denoted, the small intestine is the major site of absorption of small molecules, which
304 can occur passively through diffusion or actively through various transporter systems in
305 the gut wall(L R Johnson, 2007). Further processing of materials can then take place
306 within epithelia, e.g. lipid packing into chylomicrons. Transit time through the small
307 intestine varies according to the diet caloric density; the rheological/mechanical

308 properties (e.g. viscosity or gelling) and with consumer parameters, such as age and
309 health (e.g. 2h for healthy adult and 3h for infant(Blanquet, et al., 2004)).

310 2.4 Large intestinal phase

311 Undigested and un-absorbed foodstuffs and bodily secretions transit into the large
312 intestine through the ileocecal valve. In this last part of the human GI tract, water and
313 electrolytes are re-absorbed and bacterial fermentation of fiber and un-digestible food
314 components occurs before bulk material is excreted(Moran & Jackson, 1992). The colon
315 is increasingly recognized for its milieu of bacteria, fungi, protozoa and archaea and rich
316 metabolic activity equated to that of the human liver(Nardone & Malfertheiner, 2011;
317 O'Hara & Shanahan, 2006; Olszewska & Jagusztyn-Krynicka, 2012; Turnbaugh, et al.,
318 2007). Recent studies of the human colon microbiome have established various links
319 between nutrition, the microbiome and health with evidence that microbiomes are
320 affected by age, gender, diet, culture, geography and various physiological/pathological
321 states(Albenberg & Wu, 2014; D'Argenio, et al., 2013; Flint, 2012; Holscher, et al., 2015;
322 Olszewska & Jagusztyn-Krynicka, 2012). Therefore, it is no surprise that the field of IVD
323 models of the human colon are also a vibrant field, as reviewed by others(Payne, et al.,
324 2012). In essence, the colon hosts immense bacterial counts in three distinct loci: the
325 proximal, transverse and distal colon, which vary in their steady state pH with values of
326 5.8, 6.2 and 6.8, respectively with transit times of 12-36h. Metabolically, the microbiome
327 is highly active with both glycolytic and proteolytic activities noted and about 90% of
328 fermented indigestible polysaccharides being metabolized into short-chain fatty acids. In
329 addition, the mucosa lining of the colon is a major site for passive absorption of small
330 metabolites and close interactions with the immune system(Clemente, Ursell, Parfrey, &
331 Knight, 2012).

332 3. IVD models for specific populations

333 3.1. Infants

334 The functionality of human gastro intestinal tract (GIT) develops in the first year of life
335 with newborns (< 28 days of life) and infants up to six months possessing an immature
336 digestive system compared to older infants (>6 months) or the fully mature GI of an adult
337 (**Figure 1**). Moreover, prematurity affects strongly the digestive capabilities, with
338 decreased GI functionality in preterm babies compared to full-term newborns(J Bruce,
339 2012; D. Kelly & Coutts, 2000; E. J. Kelly & Newell, 1994; Ménard, Monfils, &
340 Tremblay, 1995). In fact, there are various differences between infants and adults mainly
341 in some digestive enzymes and a relatively elevated gastric pH (3.5-6.5), as exhaustively
342 reviewed(Abrahamse, et al., 2012; Bourlieu, et al., 2014; T. T. Nguyen, Bhandari,
343 Cichero, & Prakash, 2015a, 2015b). Briefly, infant digestion process neglects oral phase
344 due to liquid meals rapidly transiting through the oral cavity (5-10 sec). Small stomach
345 storage capacity, affecting meal frequency, transit and volume, increases quickly during
346 the first month of life from 10-20 mL up to 90-150 mL per meal(Abrahamse, et al., 2012;
347 Bourlieu, et al., 2014). Infant fasting gastric pH is less acidic than of an adult
348 (respectively 4-5 vs. 2 in the fasted state) which may change gastric proteolysis, as
349 optimal activity of pepsin is 1.5-2.2(Henderson, Hamosh, Armand, Mehta, & Hamosh,
350 1998; Li-Chan & Nakai, 1989; Schlamowitz & Peterson, 1959). Reduced pepsin
351 secretion in newborns, 10-20% from adult levels, is another physiological reason
352 explaining the limited gastric proteolysis (15%) reported for infants(Bourlieu, et al.,
353 2014; Didier Dupont, et al., 2010; Romano, Giosafatto, Masi, & Mariniello, 2015).
354 Pepsin secretion increases with postnatal age and is more immature in preterm
355 infants(AC, 1991a).

356 In respect to intestinal digestion, proteolysis in infants has similar pH and trypsin
357 concentrations as those in the intestine of adults, whereas chymotrypsins and
358 carboxypeptidases-B just account for about 10% to 60% of the activity found in
359 adults(Edginton & Fotaki, 2010; Lebenthal & Lee, 1980). Regarding lipid digestion,
360 gastric lipase activity and output are similar in preterm(Roman, et al., 2007), full-term
361 infants and adults(Armand, et al., 1996; Sarles, Moreau, & Verger, 1992). However,
362 pancreatic lipases do vary between infants and adults with pancreatic triglyceride lipase
363 (PTL) being the dominant intestinal lipolytic enzyme in adults while PTL-related protein
364 2 and bile salt-stimulated lipase are the key lipases in infants(Lindquist & Hernell, 2010).
365 In light of the high fat diet of infants(Hamosh, 2006), human breast milk contains
366 endogenous lipase (bile salt-stimulated lipase mainly, 3.6-5.3 U/mL of milk) that
367 compensates for the low amount of pancreatic lipases (5-10% the concentration found in
368 adults) and low concentration of bile salts (50% of adult values)(Lebenthal, Lee, &
369 Heitlinger, 1983). Regarding carbohydrate digestion, scarce data suggests low values of
370 pancreatic amylase are found in the GI of infants aged less than 6 months. Thus,
371 carbohydrate digestion in infants is believed to be highly facilitated by swallowed
372 salivary α -amylase (at birth average of 10 % of the adult level but highly
373 variable(Christian, Edwards, & Weaver, 1999; Sevenhuysen, Holodinsky, & Dawes,
374 1984)) or mammary α -amylase. In addition, reports also indicate the infant GI performs
375 carbohydrate digestion through lactase, sucrose-isomaltase and glucoamylase (with
376 activities of ~50% above that of adults)(Bourlieu, et al., 2014; T. T. Nguyen, et al.,
377 2015a).

378 Another important step in infant GI maturation is colonic colonization of the infant gut
379 with microbiota, which begins at birth and is an important player in the maturation and
380 education of the immune system. Development of the infant microbiota is characterized
381 by rapid and large changes in microbial abundance, diversity and composition, until
382 around 3 years of age when the microbiota becomes adult-like(Matamoros, Gras-Leguen,
383 Le Vacon, Potel, & de La Cochetiere, 2013). Introduction of solid foods into the infant
384 diet leads to a marked shift in microbial composition with an increase in clostridial
385 species and a decrease in *Bifidobacterium* and *Enterobacteriaceae*. Many factors may
386 influence the development of the gut microbiota in infants, such as mode of delivery, type
387 of maternal diet, geographical location and consumption of antibiotics(Arrieta, Stiemsma,
388 Amenyogbe, Brown, & Finlay, 2014).

389 Based on the current physiological knowledge of the infant GI, various static and
390 dynamic IVD models have been applied by researchers(Blanquet, et al., 2004; de
391 Oliveira, et al., 2015; D. Dupont, et al., 2010; Roussel C, 2016; Shani-Levi, et al., 2013).
392 Yet, the development of a harmonized static infant IVD is needed. One of the most
393 formidable challenges in this respect is the clear definition of the consumer being
394 recreated since digestive parameters are highly affected by gestational and postnatal age.
395 For instance preterm newborns compared to full-terms of same age have higher gastric
396 pH resulting from more frequent feeding, lower pepsin activity (10% of adult activity at
397 four weeks vs. 30% in full-terms), faster gastric emptying, more limited gallbladder
398 contraction index, lower concentration of electrolytes in pancreatic fluid, no amylase
399 secretion and lower global pancreatic activity(Bourlieu, et al., 2014).

400 To date, several studies have depicted static infant IVD models applied for studying
401 various aspects of protein and lipid digestion. These various models are summarized in
402 **Table 2**. As can be noted, various discrepancies are found in these models and include
403 discrepancies in gastric pH, ill-defined enzymatic proteolytic activity of enzymes and
404 large variance in experimental duration. For example, the enzyme activity was most of
405 the time not checked experimentally or based on the supplier's general characteristics,
406 which hampered experiment replication in other laboratory. After an estimation of the
407 pepsin units per mL of milk, a very large range of values was observed, ranging from 4 to
408 18563 U/mL of milk (**Table 2**). An *in vivo* study by Armand et al. (1996) reported an
409 average postprandial value of 63 U/mL of gastric content/kg of bodyweight of preterm
410 infants, which would correspond to 425 U/mL of milk for a term newborn of 4.25 kg and
411 a meal to secretion ratio of 63:39 v/v(Armand, et al., 1996). In respect to the intestinal
412 phase, pH was homogeneous (6.5 -7.5), but duration varied largely from 5 to 120 min and
413 the meal proportion in the total volume varied from 25 up to 76 %. After an estimation of
414 pancreatin content within each model, a factor of 30 between the maximum and the
415 minimum values was found across models, which remains lower than that for pepsin (a
416 4500 fold difference). Bile salts, arising from a porcine or bovine bile extract or from
417 purified bile salts, were estimated to vary by a factor of 10 across models.

418 In all models presented in **Table 2**, no clear definition of the infant stage was given,
419 except for Fogleman et al. (2012)(Fogleman, Cohen, Sakamoto, & Allen, 2012), who
420 aimed to mimic preterm infant digestion. Further, there are some dynamic IVD models
421 described in recent literature(Blanquet, et al., 2004; Ménard, et al., 1995; Menard, et al.,
422 2014; Shani-Levi, et al., 2013) (de Oliveira, et al., 2015; Havenaar, et al., 2013; Roussel

423 C, 2016). In essence, these models try to recreate some of the dynamic aspects of
424 digestion, e.g. gastric pH profiles post meal ingestion and gastric emptying rates. One of
425 these has even been validated against *in vivo* data of proteolysis kinetics obtained in
426 piglets(Menard, et al., 2014). The TIM model developed by TNO (Netherlands) was
427 adapted to simulate the GI of newborns, infants and toddlers (0–1, 1–6, and 6–24 months
428 of age, respectively) after ingestion of various types of food (formula milk, milk and
429 cereals) and validated for these three age groups against published pharmacokinetic data
430 on paracetamol(Havenaar, et al., 2013). However, in this study, not all GI parameters
431 applied to this commercial IVD model have been made publicly available. The same
432 model has been very recently adapted to mimic, based *on in vivo* data, the gastric and
433 small intestinal conditions of infant from 6 months to 2 years(Roussel C, 2016). Some
434 dynamic colonic models have also been developed(C Cinquin, Le Blay, Fliss, & Lacroix,
435 2004; Cécile Cinquin, Le Blay, Fliss, & Lacroix, 2006a, 2006b). The composition and
436 diversity of the bacterial community, as well as its metabolism, was found to be well
437 correlated with those found *in vivo* in infant feces.

438 Altogether, infant IVD models are increasing in their applicability to food research,
439 however, the variances and discrepancies found in current infant IVD model call for
440 future efforts to better define a simple, harmonized and consensus infant static IVD
441 model, such as that obtained for an adult IVD model(Minekus, et al., 2014) as well as
442 sophisticated dynamic IVD models. All of these should be developed with a rationale
443 similar to that applied by the infant formula industry, *i.e.* focusing on specific and defined
444 target populations such as stage one for 0-3 months, stage 2 for 3-6 months etc.

445 3.2. Elderly

446 Elderly nutrition, pharmacology and overall health care have been identified as one of the
447 rising global challenges(UN, 2013). Ageing is typically accompanied by a milieu of
448 changes including substantiated alterations and deterioration of gut functions, such as
449 secretion of digestive fluids and enzymes, saliva, GIT contractions and chyme passage
450 rates(Di Francesco, et al., 2005; Feldman, Cryer, McArthur, Huet, & Lee, 1996; Laugier,
451 Bernard, Berthezene, & Dupuy, 1991; Nagler & Hershkovich, 2005; Russell, et al., 1993;
452 Salles, 2007; Vellas, et al., 1988). Due to the irreversible nature of the changes in GIT
453 functions, there is a growing need to deepen our understanding of foods' digestive fate in
454 the elderly GI. This would facilitate rational design of foods to accommodate elderly
455 physiological capabilities, improve nutrient bioaccessibility and bioavailability and help
456 combat elderly malnutrition. Despite comprehensive knowledge on the GI deterioration
457 with age and its ramifications to elderly malnutrition(Remond, et al., 2015), there are
458 scant IVD models of the elderly GI found in literature. One most recent study assessed
459 the antioxidant capacity of a milk protein matrix in aged women, both *in vitro* and *in*
460 *vivo*(Power-Grant, et al., 2016). However, the target population of the study focused
461 solely on women in the ages of 50-70. In relation to IVD models recreating elderly
462 digestive conditions, two recent studies have been identified to apply *in vivo* data to the
463 modeling parameters (Denis, et al., 2016; Levi & Lesmes, 2014). The first reports the
464 set-up of a dynamic gastro-intestinal elderly (> 70 years old) model based on commercial
465 bioreactors with details on all the parameters used and the rationale of their
466 selection(Levi & Lesmes, 2014). The second, reports an adaptation of the TNO
467 gastrointestinal model (TIM) to the specific digestive conditions of the elderly (> 65
468 years old) and is used to study meat protein dynamic digestion(Denis, et al., 2016). A

469 summary of the digestive conditions applied in these models are given in **Figure 2**, also
470 summarizes conditions of the elderly population at the colon. Similar to the field of infant
471 IVD modelling, elderly digestion models require not only harmonization but also
472 validation and clearer definition of the elderly being studied.

473 3.3. Developing IVDs for humans with GI disorders

474 In light of the centrality of the GI system in human health and disease, various studies
475 present information on human GI disorders. These are defined as diseases and/or
476 conditions that interfere with the intake, digestion, and/or absorption of nutrients, causing
477 various clinical symptoms and are broadly defined as maldigestion. Physiologically, the
478 spectrum and underlying causes of GI disorders is immense from such conditions causing
479 discomfort (e.g. lactose malabsorption) to those compromising health (e.g. pancreatic
480 insufficiency in cystic fibrosis patients). All in all, these conditions arise from altered GI
481 functions which lead to various effects on the disintegration, breakdown and uptake of
482 nutrients and consequently on health(Högenhauer, 2010). Some common factors that
483 interfere with food digestion and related disorders, infections and surgical procedures
484 linked to them are summarized in **Table 3**. In respect to food breakdown and
485 bioaccessibility, many of the situations described may be mirrored using IVD models, as
486 such conditions have been found to arise from variance and abnormalities in digestive
487 parameters such as changes in gastric/intestinal pH, secretion of digestive juices and
488 transit times. Other disorders such as food allergies, autoimmune disorders (celiac sprue),
489 Crohn's disease, obesity or diabetes are linked to interferences with the absorption and/or
490 metabolism of nutrients from the food(Nolan, Johnston, & Walters, 2012), hence IVD
491 models for such conditions require much more sophistication in their *in vitro* recreation,

492 if at all feasible. Yet, efforts to develop IVD models for specific strata of the population
493 would offer useful tools not only in the development of new tailored foods but also
494 improving relevant nutritional guidelines.

495 One example for such a potential novel IVD model is for the community of Cystic
496 Fibrosis (CF) patients that has over 35,000 cases registered in Europe(Colombo &
497 Littlewood, 2011). At least 85% of CF patients have pancreatic insufficiency of lipases,
498 resulting in fat malabsorption and binding patients to the use of pancreatic enzyme
499 supplements. Armand et al. (2004) studied the effect of diet on gastric lipase levels and
500 fat digestion in children with CF and reported that gastric lipase was high in cystic
501 fibrosis patients maintained on fat-rich diets(Armand, et al., 2004). Further, Gelfond et al.
502 (2013) measured the intestinal pH and GI transit profiles in CF patients(Gelfond, Ma,
503 Semler, & Borowitz, 2013). Based on this and other *in vivo* reports, the development of
504 an IVD model of a CF patient need to focus on the unique secretion of pancreatic fluid
505 and bile, both critical parameters in lipid digestion. Analytical studies show a 3.8-fold
506 higher content of glycoconjugates than tauroconjugates in human aspirates(Brodlie, et al.,
507 2015). Thus, artificial bile should reflect composition and imbalances between tauro- and
508 glycol-conjugates isomers and bile concentration should be low to reflect the decreased
509 bile secretion (1mM). In respect to enzymatic activity, CF patients are pancreatic
510 insufficient when pancreas function is below 10% than that of a healthy adult. Then, the
511 pancreatine activity in a CF model should be 10-fold lower than that considered in
512 healthy adults.

513 Another potential IVD model to be developed is that of Gastric Bypass (GBP) patients
514 (bariatric surgery patients). GBP surgery is one of the most common and effective

515 treatments for morbid obesity but can also be used to address conditions such as type 2
516 diabetes or hypertension. Available physiological literature data on the digestive process
517 are limited to indirect, with postprandial serum or urine measurements or scintigraphy
518 evaluation of gastric emptying. Gastric emptying is reported to be very rapid for liquids,
519 based on D-xylose in serum, from 18.6 ± 6.9 min prior to GBP to 7.9 ± 2.7 min after
520 GBP(Wang, et al., 2012). Extremely rapid pouch emptying was reported for water vs.
521 whey proteins vs. olive oil as preloads (30 min) for a liquid glucose drink (t_{50} 3.8 ± 0.9 vs.
522 4.1 ± 0.6 vs. 3.6 ± 0.5 min, respectively) and for a solid beef patty meal (1.6 ± 0.7 vs. 1.1 ± 0.6
523 vs. 1.3 ± 0.5 min, respectively) (N. Q. Nguyen, et al., 2016). Bojsen-Moller et al. (2015)
524 (Bojsen-Moller, et al., 2015) observed accelerated caseinate digestion and amino acid
525 absorption (C^{13} leucine), resulting in faster and higher but more transient postprandial
526 elevation of plasma amino acids. Overall, the incidence of a dumping syndrome, defined
527 as a rapid gastric emptying, is also elevated after GBP(Horowitz, Collins, Harding, &
528 Shearman, 1985).

529 Sleeve Gastrectomy (SG), whereby the stomach duodenum connection remains intact but
530 the volume of the stomach is drastically reduced, has been also been used as an option for
531 surgical treatment of obesity. In such patients, gastric emptying half times (t_{50}) were
532 reported to be drastically reduced for both liquids and solids food (SG vs. control group:
533 34.9 ± 24.6 vs. 13.6 ± 11.9 min for water and 78 ± 15.01 vs. 38.3 ± 18.77 min for solids [egg
534 sandwich])(Horowitz, et al., 1985). The growing body of evidence on the ramifications of
535 GBP procedures on GI function could enable the development of a relevant IVD model.
536 Such a model would require a short gastric phase between 30 and 60 minutes, probably
537 coupled with a higher pH of 3.5-4.0 compared to the pH 3.0 used in an adult IVD model.

538 However, without luminal data, only estimates are possible. Yet, a comprehensive effort
539 should be done to mine the literature or conduct *in vivo* experiments to determine
540 enzymatic activity of pepsin and pancreatic enzymes as well as bile compositions.

541 The examples of CF and GBP patients are only two possibilities for novel IVD models
542 that can be developed and subsequently validated. Other GI conditions and abnormalities
543 can be recreated in IVD models pending relevant *in vivo* data is collected or found in
544 scientific literature. These stress out the potential of expanding the horizons of IVD
545 models based on the rationale exploitation of medical research.

546 **4. Conclusion**

547 The current modern food production system is complex, dynamic and constantly strives
548 to fabricate safe and nutritious food products and solutions. Amongst the various efforts,
549 researchers and manufacturers seek to rationally process, structure and formulate foods
550 towards healthier outcomes for the consumer. These include development of food
551 delivery systems for protection of bioactives ingredients added to food, controlling and
552 targeting their release in the human gastrointestinal tract and affecting various dimensions
553 of consumer well-being, e.g. shaping the colon microbiome or inducing satiety and
554 satiation. All of these efforts rely on understanding the underlying principles guiding
555 food's digestive fate. An understanding, which can be significantly advanced thanks to
556 the soaring number of studies using *in vitro* and *in vivo* digestion models.

557 As part of the food-health revolution and evolution of food manufacturing towards
558 tailored and personalized foods, the potential of IVD models could be maximized when
559 extended to recreate various strata of the human population. The development of IVD
560 models should rely on better and extensive understanding of *in vivo* digestion conditions

561 in different groups of the population but would offer better opportunities to develop
562 relevant products with high bioefficacy. Evidently, such novel tools for food and
563 nutritional research would necessitate adequate standardization and validation to ensure
564 synchronization of efforts and success. Such efforts would also greatly benefit from the
565 deposition and gathering of relevant information in a database where food and health care
566 professionals could upload *in vivo* data or *in vivo in vitro* correlations and put together
567 pieces of puzzles needed in the development of new IVD models. In light of the concern
568 over rising prevalence of chronic diseases and challenges in feeding the world, nutritional
569 management of health and disease prevention are challenges at the footsteps of dedicated
570 professionals. The authors of this paper hope that it will stimulate relevant progress in the
571 field and help orchestrate global efforts towards the shared goal of advancing food
572 science and technology.

573

574

575

576

577

578

579 **Table and Figure Captions**

580 **Table 1.** Physiological characterization of human gastro-intestinal fluids.

581

582 **Table 2.** Literature review of the proposed *in vitro* static models for infant gastro-
583 intestinal digestion.

584

585 **Table 3.** Factors interfering with food digestion and related disorders.

586

587 **Figure 1.** Summary of the developing digestive physiology in the human infant. HGL-
588 Human Gastric Lipase, PTL- pancreatic triglyceride lipase, BSSL-bile salt-stimulated
589 lipase, PTLRP2- pancreatic triglyceride lipase-related protein 2.

590

591 **Figure 2.** Summary of the developing digestive physiology in the elderly.

592

593 **Table and Figure**

594 **Table 1**

| | Fasted | Fed | Suggested References |
|--|--|--|--|
| Oral phase pH Fluid output Transit time of meal | 6; 6.2 – 7.4 0.5 mL/h | 7 ; 7.4-7.6 10 mL per meal 10 sec – 2 min | Guyton A.C. 1991(AC, 1991a) Versantvoorf C.H.M. 2004(C. H. M. Versantvoort, Oomen, Van de Kamp, Rompelberg, & Sips, 2005) Guerra A. 2012(Guerra, et al., 2012) |
| Gastric phase pH Gastric lipase Transit time of meal | 1.5 - 2.0 120 - 130 U/mL | 3.0 – 7.0 15 min – 3 hours | Dressman J.B.1986(Dressman, et al., 1990) Sams L. 2016(Sams, et al., 2016) Guerra A. 2012(Guerra, et al., 2012) |
| Small intestine pH Bicarbonate secretion Total fluid output Total proteolytic activity Trypsin Output activity Chymotrypsin Output activity Amylase output activity Lipase Bile Surface tension Transit time | 5.4-6.5 15-27 mM/h 118 mL/h 5.6-25.4 U/mL | 5.5-7.5 9000/24h 212/mL 200-300/h 50-100-500 U/mL 33-77 IU/mL 70-150 U/mL bw/15min 500-1000 (U/mL) 97-450 (IU/mL) 3000-6000 (U/mL) 100-400 (U/mL) 234-524 (IU/mL) 5.8-39 uM/mL TDC ^a , GC ^b , GCDC ^c , GDC ^d 2.2-11.2mM 28mN/m 2-5h | Dressman JB. 1990(Dressman, et al., 1990) Ekmekcioglu C. 2002(Ekmekcioglu, 2002) Ulleberg E. 2011(Ulleberg, et al., 2011) |
| Large intestine pH Bacterial load Short chain fatty acids Total fluid vol Transit time | | 6.4-7.0 1x10 ¹¹ -10 ¹² CFU/g material 125-139 mM 187 ml 12-24h | Payne A.N. (Payne, et al., 2012) |

595 ^aTaurodeoxycholate; ^bGlycocholate; ^cGlycochenodeoxycholate; ^dGlycodeoxycholate

596 **Table 2**

| Refs | Meal | Gastric phase | | | | | | | Intestinal phase | | | | | |
|--|-------------------|------------------------|----------------|------------------------------|--|-----------------------------|------------------------------------|---------------------------|-------------------|----------------|------------------------------|--|---------------------------------------|-----------------------------------|
| | | pH | Duration (min) | Meal : secretion ratio (v/v) | Lipase content (/mL of meal) | Pepsin ^b content | Pepsin ^c (U/mL of meal) | Molar ratio pepsin / meal | pH | Duration (min) | Meal : secretion ratio (v/v) | Enzyme(s) used ^c | Pancreatin equivalent (mg/mL of meal) | Bile ^d (mg/mL of meal) |
| Chatterton et al., 2004(Chatterton, Rasmussen, Heegaard, Sorensen, & Petersen, 2004) | Human milk | 2, 3, 3.5, 4, 5 or 6.5 | 60 | 99 : 1 | supernatant of gastric juice from 2 neonates | | - | - | no duodenal phase | | | | | |
| Dupont et al., 2010(D. Dupont, et al., 2010) | Purified proteins | 3 | 60 | 85 : 15 | - | 22.75 U/mg of protein | 273 ^f | 0.0042 | 6.5 | 30 | 76 : 24 | Porcine trypsin : 3.45 U/mg of protein Bovine chymotrypsin : 0.04 U/mg of protein | 5.91 ^{f,h} | 1.32 ⁱ |
| Fogleman et al., 2013(Fogleman, et al., 2012) | Human milk | 5 | 120 | 66 : 34 | 42.5 mg | 2.5 mg/ml of milk | 7500 | 0.3317 | 7 | 120 | 40 : 60 | Pancreatin : 2 mg/mL of SDF ^g | 0.63 | 3.75 |

| | | | | | | | | | | | | | | |
|--|----------------|--------------------|-----|---------|---------------------------------------|---|-------|--------|-------------------|-----|---------|-----------------------------------|-----|----|
| Lueamsaisuk et al., 2014(Lueamsaisuk, Lentle, MacGibbon, Matia-Merino, & Golding, 2014) Lueamsaisuk et al., 2015(Lueamsaisuk, Lentle, MacGibbon, Matia-Merino, & Golding, 2015) | Infant formula | 2, 3.5, 4.5 or 5.5 | 120 | 20 : 50 | 40 U (<i>Rhizopus Oryzae</i> lipase) | 4.5 mg/ml of SGF ^e (800-2500 U/mg) | 18563 | 0.2829 | No duodenal phase | | | | | |
| Prakash et al., 2014(Prakash, Ma, & Bhandari, 2014) | Infant formula | 1.5 | 60 | 50 : 50 | - | 3.2 mg/ml of SGF | 9600 | 0.1463 | 7 | 120 | 25 : 75 | Pancreatin : 1.6 mg/ml of digesta | 3.2 | 10 |

597

598

599

| Refs | Meal | Gastric phase | | | | | | | Intestinal phase | | | | | |
|------|------|---------------|--|--|--|--|--|--|------------------|--|--|--|--|--|
|------|------|---------------|--|--|--|--|--|--|------------------|--|--|--|--|--|


| | | pH | Duration (min) | Meal : secretion ratio (v/v) | Lipase content (/mL of meal) | Pepsin ^b content | Pepsin ^c (U/mL of meal) | Molar ratio pepsin / meal | pH | Duration (min) | Meal : secretion ratio (v/v) | Enzyme(s) used ^c | Pancreatin equivalent (mg/mL of meal) | Bile ^d (mg/mL of meal) |
|--|---|-----|-------------------------------------|------------------------------|------------------------------|-----------------------------|------------------------------------|---------------------------|-----|----------------|------------------------------|-------------------------------------|---------------------------------------|-----------------------------------|
| Wada & Lonnerdal, 2014(Wada & Loennerdal, 2014) Wada & Lonnerdal, 2015(Wada & Loennerdal, 2015) | Defatted bovine milk Defatted human milk | 4 | 15 | - | - | 0.08 mg /mg of protein | 2880 ^f | 0.020 0.044 | 7 | 5 | - | Pancreatin: protein ratio of 1:62.5 | 0.19 ^f | - |
| Dall'Asta et al., 2015(Dall'Asta, et al., 2015) | Human milk | 4.5 | 35 | 15 : 9 | - | 0.013 mg/ml of milk | 4.0 | 0.0001 | 7.5 | 120 | 15 : 20 | Porcine pancreatin : 9 mg/mL of SDF | 3.6 | 6 (bovine bile) |
| N-Guyen et al., 2015(T. T. Nguyen, et al., 2015a) | Infant formula | 4 | As detailed for Dupont et al., 2010 | | | | | | | | | | | |
| Liu et al., 2016(Liu, et al., 2016) | Milk protein concentrate | 3 | 60 | 50 : 50 | - | 113.8 U/ml of SGF | 113.8 | 0.0008 | 6.5 | 60 | 25 : 75 | Bovine trypsin : 8.6 U/ml of SDF | 2.46 ^h | 4 ⁱ |

600 **Table 3**

| Causes of maldigestion | Related diseases | Impact |
|--|---|---|
| Digestive enzyme deficiency | Chronic pancreatitis, cystic fibrosis, pancreatic carcinoma | Hydrolysis of proteins, carbohydrates and fats |
| Digestive enzyme inactivation by excess of HCl | Zollinger-Ellison syndrome | |
| Dissynchrony of enzyme release and inadequate mixing | Hyperthyroidism, post billroth ii procedure (gastrojejunostomy), gastric bypass | |
| Diminished bile salt synthesis | Cirrhosis | Fat solubilisation Fat soluble vitamins absorbtion |
| Impared bile secretion | Cystic fibrosis, chronic cholestasis | |
| Increased bile salt loss | Ileal disease or resection | |
| Bile salt de-conjugation | Bacterial: overgrowth | |
| Bacterial consumption of nutrients | Bacterial overgrowth associated to B12 deficiency | Bioavailability of specific nutrients |
| Reduced gastric acid | Atrophic gastritis associated to B12 deficiency | |
| Reduced intrinsic factor | Pernicious anemia associated to B12 deficiency | |
| Cofactors deficiency | Gastric surgery | |


601
602
603
604
605
606
607
608
609

610 **Figure 1**



611

612 **Figure 2**



613

614

615 5. References

- 616 Abrahamse, E., Minekus, M., van Aken, G. A., van de Heijning, B., Knol, J., Bartke, N., Oozeer, R.,
617 van der Beek, E. M., & Ludwig, T. (2012). Development of the digestive system—
618 experimental challenges and approaches of infant lipid digestion. *Food Digestion*, *3*, 63-
619 77.
- 620 AC, G. (1991a). *Textbook of medical physiology*. Philadelphia.
- 621 Aken, G. A. v., Vingerhoeds, M. H., & Wijk, R. A. d. (2011). Textural perception of liquid
622 emulsions: Role of oil content, oil viscosity and emulsion viscosity. *Food Hydrocolloids*,
623 *25*, 789-796.
- 624 Albenberg, L. G., & Wu, G. D. (2014). Diet and the Intestinal Microbiome: Associations,
625 Functions, and Implications for Health and Disease. *Gastroenterology*, *146*, 1564-1572.
- 626 Aps, J. K. M., & Martens, L. C. (2005). Review: The physiology of saliva and transfer of drugs into
627 saliva. *Forensic Science International*, *150*, 119-131.
- 628 Armand, M., Hamosh, M., Mehta, N. R., Angelus, P. A., Philpott, J. R., Henderson, T. R., Dwyer, N.
629 K., Lairon, D., & Hamosh, P. (1996). Effect of Human Milk or Formula on Gastric Function
630 and Fat Digestion in the Premature Infant1. *Pediatric Research*, *40*, 429-437.
- 631 Armand, M., Hamosh, M., Philpott, J. R., Resnik, A. K., Rosenstein, B. J., Hamosh, A., Perman, J.
632 A., & Hamosh, P. (2004). Gastric function in children with cystic fibrosis: effect of diet on
633 gastric lipase levels and fat digestion. *Pediatric Research*, *55*, 457-465.
- 634 Arrieta, M.-C., Stiemsma, L. T., Amenyogbe, N., Brown, E. M., & Finlay, B. (2014). The intestinal
635 microbiome in early life: health and disease. *Front Immunol*, *5*, 3389.
- 636 Blanquet, S., Zeijdner, E., Beyssac, E., Meunier, J. P., Denis, S., Havenaar, R., & Alric, M. (2004). A
637 dynamic artificial gastrointestinal system for studying the behavior of orally
638 administered drug dosage forms under various physiological conditions. *Pharmaceutical
639 Research*, *21*, 585-591.
- 640 Boivin, M., Lanspa, S. J., Zinsmeister, A. R., Go, V. L. W., & Dimagno, E. P. (1990). ARE DIETS
641 ASSOCIATED WITH DIFFERENT RATES OF HUMAN INTERDIGESTIVE AND POSTPRANDIAL
642 PANCREATIC-ENZYME SECRETION. *Gastroenterology*, *99*, 1763-1771.
- 643 Bojsen-Moller, K. N., Jacobsen, S. H., Dirksen, C., Jorgensen, N. B., Reitelseder, S., Jensen, J.-E. B.,
644 Kristiansen, V. B., Holst, J. J., van Hall, G., & Madsbad, S. (2015). Accelerated protein
645 digestion and amino acid absorption after Roux-en-Y gastric bypass. *American Journal of
646 Clinical Nutrition*, *102*, 600-607.
- 647 Bornhorst, G. M., Gouseti, O., Wickham, M. S. J., & Bakalis, S. (2016). Engineering Digestion:
648 Multiscale Processes of Food Digestion. *Journal of Food Science*, *81*, R534-R543.
- 649 Bourlieu, C., Ménard, O., Bouzerzour, K., Mandalari, G., Macierzanka, A., Mackie, A. R., &
650 Dupont, D. (2014). Specificity of infant digestive conditions: some clues for developing
651 relevant in vitro models. *Critical Reviews in Food Science and Nutrition*, *54*, 1427-1457.
- 652 Brodlie, M., Aseeri, A., Lordan, J. L., Robertson, A. G. N., McKean, M. C., Corris, P. A., Griffin, S.
653 M., Manning, N. J., Pearson, J. P., & Ward, C. (2015). Bile acid aspiration in people with
654 cystic fibrosis before and after lung transplantation. *European Respiratory Journal*, *46*,
655 1820-1823.
- 656 Campbell, I. (2015). The mouth, stomach and intestines. *Anaesthesia and Intensive Care
657 Medicine*, *16*, 37-39.
- 658 Chatterton, D. E. W., Rasmussen, J. T., Heegaard, C. W., Sorensen, E. S., & Petersen, T. E. (2004).
659 In vitro digestion of novel milk protein ingredients for use in infant formulas: Research
660 on biological functions. *Trends in Food Science & Technology*, *15*, 373-383.

661 Christian, M., Edwards, C., & Weaver, L. T. (1999). Starch digestion in infancy. *Journal of*
662 *pediatric gastroenterology and nutrition*, 29, 116-124.

663 Cinquin, C., Le Blay, G., Fliss, I., & Lacroix, C. (2004). Immobilization of infant fecal microbiota
664 and utilization in an in vitro colonic fermentation model. *Microbial Ecology*, 48, 128-138.

665 Cinquin, C., Le Blay, G., Fliss, I., & Lacroix, C. (2006a). Comparative effects of exopolysaccharides
666 from lactic acid bacteria and fructo-oligosaccharides on infant gut microbiota tested in
667 an in vitro colonic model with immobilized cells. *FEMS microbiology ecology*, 57, 226-
668 238.

669 Cinquin, C., Le Blay, G., Fliss, I., & Lacroix, C. (2006b). New three-stage in vitro model for infant
670 colonic fermentation with immobilized fecal microbiota. *FEMS microbiology ecology*, 57,
671 324-336.

672 Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012). The Impact of the Gut Microbiota
673 on Human Health: An Integrative View. *Cell*, 148, 1258-1270.

674 Colombo, C., & Littlewood, J. (2011). The implementation of standards of care in Europe: state
675 of the art. *Journal of Cystic Fibrosis*, 10, S7-S15.

676 D'Argenio, V., Precone, V., Casaburi, G., Miele, E., Martinelli, M., Staiano, A., Salvatore, F., &
677 Sacchetti, L. (2013). An Altered Gut Microbiome Profile in a Child Affected by Crohn's
678 Disease Normalized After Nutritional Therapy. *The American Journal of*
679 *Gastroenterology*, 108, 851-852.

680 Dall'Asta, C., Florio, P., Lammardo, A. M., Prandi, B., Mazzeo, T., Budelli, A., & Pellegrini, N.
681 (2015). Development of an in vitro digestive model for studying the peptide profile of
682 breast milk. *International Journal of Food Sciences and Nutrition*, 66, 409-415.

683 de Oliveira, S. C., Deglaire, A., Ménard, O., Bellanger, A., Rousseau, F., Henry, G., Dirson, E.,
684 Carrière, F., Dupont, D., & Bourlieu, C. (2015). Holder pasteurization impacts the
685 proteolysis, lipolysis and disintegration of human milk under in vitro dynamic term
686 newborn digestion. *Food Research International*.

687 Deat, E., Blanquet-Diot, S., Jarrige, J.-F., Denis, S., Beyssac, E., & Alric, M. (2009). Combining the
688 Dynamic TNO-Gastrointestinal Tract System with a Caco-2 Cell Culture Model:
689 Application to the Assessment of Lycopene and alpha-Tocopherol Bioavailability from a
690 Whole Food. *Journal of Agricultural and Food Chemistry*, 57, 11314-11320.

691 Deat, E., Blanquet-Diot, S., Jarrige, J. F., Denis, S., Beyssac, E., & Alric, M. (2009). Combining the
692 Dynamic TNO-Gastrointestinal Tract System with a Caco-2 Cell Culture Model:
693 Application to the Assessment of Lycopene and alpha-Tocopherol Bioavailability from a
694 Whole Food. *Journal of Agricultural and Food Chemistry*, 57, 11314-11320.

695 Dekkers, B. L., Kolodziejczyk, E., Acquistapace, S., Engmann, J., & Wooster, T. J. (2016). Impact of
696 gastric pH profiles on the proteolytic digestion of mixed [small beta]lg-Xanthan
697 biopolymer gels. *Food & Function*, 7, 58-68.

698 Denis, S., Sayd, T., Georges, A., Chambon, C., Chalancon, S., sante-lhoutellier, v., & Blanquet-
699 Diot, S. (2016). Digestion of cooked meat proteins is slightly affected by age conditions
700 as assessed using the dynamic gastrointestinal TIM model and mass spectrometry. *Food*
701 *& Function*.

702 DeSesso, J. M., & Jacobson, C. F. (2001). Anatomical and physiological parameters affecting
703 gastrointestinal absorption in humans and rats. *Food and Chemical Toxicology*, 39, 209-
704 228.

705 Di Francesco, V., Zamboni, M., Dioli, A., Zoico, E., Mazzali, G., Omizzolo, F., Bissoli, L., Solerte, S.
706 B., Benini, L., & Bosello, O. (2005). Delayed postprandial gastric emptying and impaired
707 gallbladder contraction together with elevated cholecystokinin and peptide YY serum

708 levels sustain satiety and inhibit hunger in healthy elderly persons. *Journals of*
709 *Gerontology Series a-Biological Sciences and Medical Sciences*, 60, 1581-1585.

710 Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell, T. L., Schmaltz, S. P., Barnett, J. L., &
711 Jarvenpaa, K. M. (1990). Upper GI pH in Young, Healthy-Men and Women.
712 *Pharmaceutical Research*, 7, 756-761.

713 Dupont, D., Mandalari, G., Molle, D., Jardin, J., Leonil, J., Faulks, R. M., Wickham, M. S. J., Mills, E.
714 N. C., & Mackie, A. R. (2010). Comparative resistance of food proteins to adult and infant
715 in vitro digestion models. *Molecular Nutrition & Food Research*, 54, 767-780.

716 Dupont, D., Mandalari, G., Mollé, D., Jardin, J., Rolet-Répécaud, O., Duboz, G., Léonil, J., Mills, C.
717 E., & Mackie, A. R. (2010). Food processing increases casein resistance to simulated
718 infant digestion. *Molecular nutrition & food research*, 54, 1677-1689.

719 Edginton, A. N., & Fotaki, N. (2010). Oral drug absorption in pediatric populations. *Oral drug*
720 *absorption: prediction and assessment. 2nd edn. New York: Informa Healthcare*, 108-
721 126.

722 Egger, L., Ménard, O., Delgado-Andrade, C., Alvito, P., Assunção, R., Balance, S., Barberá, R.,
723 Brodkorb, A., Cattenoz, T., Clemente, A., Comi, I., Dupont, D., Garcia-Llatas, G., Lagarda,
724 M. J., Le Feunteun, S., JanssenDuijghuijsen, L., Karakaya, S., Lesmes, U., Mackie, A. R.,
725 Martins, C., Meynier, A., Miralles, B., Murray, B. S., Pihlanto, A., Picariello, G., Santos, C.
726 N., Simsek, S., Recio, I., Rigby, N., Rioux, L.-E., Stoffers, H., Tavares, A., Tavares, L.,
727 Turgeon, S., Ulleberg, E. K., Vegarud, G. E., Vergères, G., & Portmann, R. (2016). The
728 harmonized INFOGEST in vitro digestion method: From knowledge to action. *Food*
729 *Research International*.

730 Ekmekcioglu, C. (2002). A physiological approach for preparing and conducting intestinal
731 bioavailability studies using experimental systems. *Food Chemistry*, 76, 225-230.

732 Elashoff, J. D., Reedy, T. J., & Meyer, J. H. (1982). ANALYSIS OF GASTRIC-EMPTYING DATA.
733 *Gastroenterology*, 83, 1306-1312.

734 Feldman, M., Cryer, B., McArthur, K. E., Huet, B. A., & Lee, E. (1996). Effects of aging and gastritis
735 on gastric acid and pepsin secretion in humans: A prospective study. *Gastroenterology*,
736 110, 1043-1052.

737 Ferrua, M. J., & Singh, R. P. (2010). Modeling the Fluid Dynamics in a Human Stomach to Gain
738 Insight of Food Digestion. *Journal of Food Science*, 75, R151-R162.

739 Flint, H. J. (2012). The impact of nutrition on the human microbiome. *Nutrition Reviews*, 70, S10-
740 S13.

741 Floros, J. D., Newsome, R., Fisher, W., Barbosa-Cánovas, G. V., Chen, H., Dunne, C. P., German, J.
742 B., Hall, R. L., Heldman, D. R., Karwe, M. V., Knabel, S. J., Labuza, T. P., Lund, D. B.,
743 Newell-McGloughlin, M., Robinson, J. L., Sebranek, J. G., Shewfelt, R. L., Tracy, W. F.,
744 Weaver, C. M., & Ziegler, G. R. (2010). Feeding the World Today and Tomorrow: The
745 Importance of Food Science and Technology. *Comprehensive Reviews in Food Science*
746 *and Food Safety*, 9, 572-599.

747 Fogleman, A. D., Cohen, R. S., Sakamoto, P., & Allen, J. C. (2012). Addition of Calcium and
748 Phosphorus to Preterm Donor Human Milk and the Impact on Protein, Fat, and Calcium
749 Digestibility In Vitro. *ICAN: Infant, Child, & Adolescent Nutrition*, 4, 199-206.

750 Gelfond, D., Ma, C., Semler, J., & Borowitz, D. (2013). Intestinal pH and gastrointestinal transit
751 profiles in cystic fibrosis patients measured by wireless motility capsule. *Digestive*
752 *diseases and sciences*, 58, 2275-2281.

753 Glahn, R. P., Wien, E. M., VanCampen, D. R., & Miller, D. D. (1996). Caco-2 cell iron uptake from
754 meat and casein digests parallels in vivo studies: Use of a novel in vitro method for rapid
755 estimation of iron bioavailability. *Journal of Nutrition*, 126, 332-339.

756 Guerra, A., Etienne-Mesmin, L., Livrelli, V., Denis, S., Blanquet-Diot, S., & Alric, M. (2012).
757 Relevance and challenges in modeling human gastric and small intestinal digestion.
758 *Trends in Biotechnology*, *30*, 591-600.

759 Hamosh, M. (1994). *Gastric and lingual lipases*.

760 Hamosh, M. (2006). Enteral lipid digestion and absorption. *Neonatal nutrition and metabolism*,
761 350-367.

762 Havenaar, R., Anneveld, B., Hanff, L. M., de Wildt, S. N., de Koning, B. A., Mooij, M. G., Lelieveld,
763 J. P., & Minekus, M. (2013). In vitro gastrointestinal model (TIM) with predictive power,
764 even for infants and children? *International journal of pharmaceuticals*, *457*, 327-332.

765 Henderson, T. R., Hamosh, M., Armand, M., Mehta, N. R., & Hamosh, P. (1998). Gastric
766 Proteolysis in the Preterm Infant: Protein Digestion is Limited and Is Not Affected by
767 Diet, Human Milk or Formula† 580. *Pediatric Research*, *43*, 101-101.

768 Hofmann, A. F. (1999). The continuing importance of bile acids in liver and intestinal disease.
769 *Archives of Internal Medicine*, *159*, 2647-2658.

770 Högenhauer, C., Hammer, H.F. . (2010). *Maldigestion and malabsorption*. (9 ed.). Philadelphia:
771 WB Saunders.

772 Holmes, R., & Lobley, R. W. (1989). INTESTINAL BRUSH-BORDER REVISITED. *Gut*, *30*, 1667-1678.

773 Holscher, H. D., Caporaso, J. G., Hooda, S., Brulc, J. M., Fahey, G. C., Jr., & Swanson, K. S. (2015).
774 Fiber supplementation influences phylogenetic structure and functional capacity of the
775 human intestinal microbiome: follow-up of a randomized controlled trial. *American
776 Journal of Clinical Nutrition*, *101*, 55-64.

777 Horowitz, M., Collins, P., Harding, P., & Shearman, D. (1985). Gastric emptying after gastric
778 bypass. *International Journal of Obesity*, *10*, 117-121.

779 Hur, S. J., Lim, B. O., Decker, E. A., & McClements, D. J. (2011). In vitro human digestion models
780 for food applications. *Food Chemistry*, *125*, 1-12.

781 J Bruce, G. (2012). Digestion of Protein in Premature and Term Infants. *Journal of Nutritional
782 Disorders & Therapy*.

783 Johnson, L. R. (2007). *Gastrointestinal Physiology* (7th ed.). Philadelphia: Mosby Elsevier.

784 Johnson, L. R. (2007). Gastrointestinal Physiology. In J. L. R (Ed.), (7th ed.). Philadelphia, PA:
785 Mosby Elsevier.

786 Johnston, N., Dettmar, P. W., Bishwokarma, B., Lively, M. O., & Koufman, J. A. (2007).
787 Activity/stability of human pepsin: Implications for reflux attributed laryngeal disease.
788 *Laryngoscope*, *117*, 1036-1039.

789 Joost, H.-G., Gibney, M. J., Cashman, K. D., Gorman, U., Hesketh, J. E., Mueller, M., van Ommen,
790 B., Williams, C. M., & Mathers, J. C. (2007). Personalised nutrition: status and
791 perspectives. *British Journal of Nutrition*, *98*, 26-31.

792 Kalantzi, L., Goumas, K., Kalioras, V., Abrahamsson, B., Dressman, J. B., & Reppas, C. (2006).
793 Characterization of the human upper gastrointestinal contents under conditions
794 simulating bioavailability/bioequivalence studies. *Pharmaceutical Research*, *23*, 165-176.

795 Keller, J., & Layer, P. (2005). Human pancreatic exocrine response to nutrients in health and
796 disease. *Gut*, *54*, 1-28.

797 Kelly, D., & Coutts, A. G. P. (2000). Development of digestive and immunological function in
798 neonates: role of early nutrition. *Livestock Production Science*, *66*, 161-167.

799 Kelly, E. J., & Newell, S. J. (1994). GASTRIC ONTOGENY - CLINICAL IMPLICATIONS. *Archives of
800 Disease in Childhood*, *71*, F136-F141.

801 Kong, F. B., & Singh, R. P. (2010a). A Human Gastric Simulator (HGS) to Study Food Digestion in
802 Human Stomach. *Journal of Food Science*, *75*, E627-E635.

803 Kong, F. B., & Singh, R. P. (2010b). Solid Loss of Carrots During Simulated Gastric Digestion. *Food*
804 *Biophysics*, *6*, 84-93.

805 Kopf-Bolanz, K. A., Schwander, F., Gijs, M., Vergeres, G., Portmann, R., & Egger, L. (2012).
806 Validation of an In Vitro Digestive System for Studying Macronutrient Decomposition in
807 Humans. *Journal of Nutrition*, *142*, 245-250.

808 Laugier, R., Bernard, J. P., Berthezene, P., & Dupuy, P. (1991). Changes in pancreatic exocrine
809 secretion with age - pancreatic exocrine secretion does decrease in the elderly.
810 *Digestion*, *50*, 202-211.

811 Lebenthal, E., & Lee, P. (1980). Development of functional response in human exocrine
812 pancreas. *Pediatrics*, *66*, 556-560.

813 Lebenthal, E., Lee, P., & Heitlinger, L. A. (1983). Impact of development of the gastrointestinal
814 tract on infant feeding. *The Journal of pediatrics*, *102*, 1-9.

815 Lefebvre, D. E., Venema, K., Gombau, L., Valerio, L. G., Jr., Raju, J., Bondy, G. S., Bouwmeester,
816 H., Singh, R. P., Clippinger, A. J., Collnot, E.-M., Mehta, R., & Stone, V. (2015). Utility of
817 models of the gastrointestinal tract for assessment of the digestion and absorption of
818 engineered nanomaterials released from food matrices. *Nanotoxicology*, *9*, 523-542.

819 Levi, C. S., & Lesmes, U. (2014). Bi-compartmental elderly or adult dynamic digestion models
820 applied to interrogate protein digestibility. *Food & Function*, *5*, 2402-2409.

821 Li-Chan, E., & Nakai, S. (1989). Enzymic dephosphorylation of bovine casein to improve acid
822 clotting properties and digestibility for infant formula. *Journal of Dairy Research*, *56*,
823 381-390.

824 Lindquist, S., & Hernell, O. (2010). Lipid digestion and absorption in early life: an update. *Current*
825 *Opinion in Clinical Nutrition & Metabolic Care*, *13*, 314-320.

826 Liu, D., Wang, Y., Yu, Y., Hu, J., Lu, N., Regenstein, J. M., Wang, M., & Zhou, P. (2016). Effects of
827 enzymatic dephosphorylation on infant in vitro gastrointestinal digestibility of milk
828 protein concentrate. *Food Chemistry*, *197*, 891-899.

829 Lueamsaisuk, C., Lentle, R. G., MacGibbon, A. K. H., Matia-Merino, L., & Golding, M. (2014).
830 Factors influencing the dynamics of emulsion structure during neonatal gastric digestion
831 in an in vitro model. *Food Hydrocolloids*, *36*, 162-172.

832 Lueamsaisuk, C., Lentle, R. G., MacGibbon, A. K. H., Matia-Merino, L., & Golding, M. (2015). The
833 effect of lactoferrin on physical changes in phospholipid stabilised emulsions during
834 neonatal in vitro gastric digestion: Does synergism of pepsin and lipase promote lipolysis
835 in protein-stabilised emulsions? *Food Hydrocolloids*, *43*, 785-793.

836 Macfarlane, G. T., Macfarlane, S., & Gibson, G. R. (1998). Validation of a Three-Stage Compound
837 Continuous Culture System for Investigating the Effect of Retention Time on the Ecology
838 and Metabolism of Bacteria in the Human Colon *Microbial Ecology*, *35*, 180-187.

839 Manione, G., Nitride, C., Picariello, G., Addeo, F., Ferranti, P., & Mackie, A. (2015). Tracking the
840 Fate of Pasta (T. Durum Semolina) Immunogenic Proteins by in Vitro Simulated
841 Digestion. *Journal of Agricultural and Food Chemistry*, *63*, 2660-2667.

842 Matamoros, S., Gras-Leguen, C., Le Vacon, F., Potel, G., & de La Cochetiere, M.-F. (2013).
843 Development of intestinal microbiota in infants and its impact on health. *Trends in*
844 *microbiology*, *21*, 167-173.

845 McClements, D. J., & Li, Y. (2010). Review of in vitro digestion models for rapid screening of
846 emulsion-based systems. *Food & Function*, *1*, 32-59.

847 Ménard, D., Monfils, S., & Tremblay, E. (1995). Ontogeny of human gastric lipase and pepsin
848 activities. *Gastroenterology*, *108*, 1650-1656.

849 Menard, O., Cattenoz, T., Guillemin, H., Souchon, I., Deglaire, A., Dupont, D., & Picque, D. (2014).
850 Validation of a new in vitro dynamic system to simulate infant digestion. *Food*
851 *Chemistry*, *145*, 1039-1045.

852 Mercuri, A., Lo Curto, A., Wickham, M. S. J., Craig, D. Q. M., & Barker, S. A. (2008). Dynamic
853 gastric model (DGM): a novel in vitro apparatus to assess the impact of gastric digestion
854 on the droplet size of self-emulsifying drug-delivery systems. *Journal of Pharmacy and*
855 *Pharmacology*, *60*, 4.

856 Miled, N., Canaan, S., Dupuis, L., Roussel, A., Riviere, M., Carriere, F., de Caro, A., Cambillau, C.,
857 & Verger, R. (2000). Digestive lipases: From three-dimensional structure to physiology.
858 *Biochimie*, *82*, 973-986.

859 Minekus, M., Alminger, M., Alvito, P., Ballance, S., Bohn, T., Bourlieu, C., Carriere, F., Boutrou, R.,
860 Corredig, M., Dupont, D., Dufour, C., Egger, L., Golding, M., Karakaya, S., Kirkhus, B., Le
861 Feunteun, S., Lesmes, U., Macierzanka, A., Mackie, A., Marze, S., McClements, D. J.,
862 Menard, O., Recio, I., Santos, C. N., Singh, R. P., Vegarud, G. E., Wickham, M. S. J.,
863 Weitschies, W., & Brodkorb, A. (2014). A standardised static in vitro digestion method
864 suitable for food - an international consensus. *Food & Function*.

865 Minekus, M., Marteau, P., Havenaar, R., & Huisintveld, J. H. J. (1995). A Multicompartmental
866 Dynamic Computer-Controlled Model Simulating the Stomach and Small-Intestine. *Atla-*
867 *Alternatives to Laboratory Animals*, *23*, 197-209.

868 Molly, K., Woestyne, M. V., & Verstraete, W. (1993). DEVELOPMENT OF A 5-STEP
869 MULTICHAMBER REACTOR AS A SIMULATION OF THE HUMAN INTESTINAL MICROBIAL
870 ECOSYSTEM. *Applied Microbiology and Biotechnology*, *39*, 254-258.

871 Moran, B. J., & Jackson, A. A. (1992). FUNCTION OF THE HUMAN COLON. *British Journal of*
872 *Surgery*, *79*, 1132-1137.

873 Nagler, R. M., & Hershkovich, O. (2005). Relationships between age, drugs, oral sensorial
874 complaints and salivary profile. *Archives of Oral Biology*, *50*, 7-16.

875 Nardone, G., & Malfertheiner, P. (2011). Gut Microbiota: The Forgotten Organ Preface. *Digestive*
876 *Diseases*, *29*, 517-517.

877 Nguyen, N. Q., Debreceni, T. L., Burgstad, C. M., Neo, M., Bellon, M., Wishart, J. M., Standfield,
878 S., Bartholomeusz, D., Rayner, C. K., Wittert, G., & Horowitz, M. (2016). Effects of Fat
879 and Protein Preloads on Pouch Emptying, Intestinal Transit, Glycaemia, Gut Hormones,
880 Glucose Absorption, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y
881 Gastric Bypass. *Obesity Surgery*, *26*, 77-84.

882 Nguyen, T. T., Bhandari, B., Cichero, J., & Prakash, S. (2015a). A comprehensive review on in vitro
883 digestion of infant formula. *Food Research International*, *76*, 373-386.

884 Nguyen, T. T., Bhandari, B., Cichero, J., & Prakash, S. (2015b). Gastrointestinal digestion of dairy
885 and soy proteins in infant formulas: An in vitro study. *Food Research International*, *76*,
886 348-358.

887 Nolan, J. D., Johnston, I. M., & Walters, J. R. (2012). Physiology of malabsorption. *Surgery*
888 *(Oxford)*, *30*, 268-274.

889 O'Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. *EMBO Rep*, *7*, 688-693.

890 O'Keefe, S. J. D., Lee, R. B., Anderson, F. P., Gennings, C., Abou-Assi, S., Clore, J., Heuman, D., &
891 Chey, W. (2003). Physiological effects of enteral and parenteral feeding on
892 pancreaticobiliary secretion in humans. *American Journal of Physiology-Gastrointestinal*
893 *and Liver Physiology*, *284*, G27-G36.

894 Olszewska, J., & Jagusztyn-Krynicka, E. K. (2012). Human Microbiome Project - influence of gut
895 microbiota on human physiology and health. *Postepy Mikrobiologii*, *51*, 243-256.

896 Payne, A. N., Zihler, A., Chassard, C., & Lacroix, C. (2012). Advances and perspectives in in vitro
897 human gut fermentation modeling. *Trends in Biotechnology*, *30*, 17-25.

898 Power-Grant, O., McCormack, W. G., De Cap, M. R., Amigo-Benavent, M., Fitzgerald, R. J., &
899 Jakeman, P. (2016). Evaluation of the antioxidant capacity of a milk protein matrix in
900 vitro and in vivo in women aged 50-70 years. *International Journal of Food Sciences and
901 Nutrition*, *67*, 325-334.

902 Prakash, S., Ma, Q., & Bhandari, B. (2014). Rheological behaviour of selected commercially
903 available baby formulas in simulated human digestive system. *Food Research
904 International*, *64*, 889-895.

905 Qi, L. (2014). Personalized nutrition and obesity. *Annals of Medicine*, *46*, 247-252.

906 Rantonen, P. (2003). *Salivary flow and composition in healthy and diseased adults*. Unpublished
907 PhD Thesis, University of Helsinki, Helsinki.

908 Remond, D., Shahar, D. R., Gille, D., Pinto, P., Kachal, J., Peyron, M. A., Dos Santos, C. N.,
909 Walther, B., Bordoni, A., Dupont, D., Tomas-Cobos, L., & Vergeres, G. (2015).
910 Understanding the gastrointestinal tract of the elderly to develop dietary solutions that
911 prevent malnutrition. *Oncotarget*, *6*, 13858-13898.

912 Roman, C., Carriere, F., Villeneuve, P., Pina, M., Millet, V., Simeoni, U., & Sarles, J. (2007).
913 Quantitative and qualitative study of gastric lipolysis in premature infants: do MCT-
914 enriched infant formulas improve fat digestion? *Pediatric Research*, *61*, 83-88.

915 Romano, A., Giosafatto, C., Masi, P., & Mariniello, L. (2015). Impact of dehulling on the physico-
916 chemical properties and in vitro protein digestion of common beans (*Phaseolus vulgaris*
917 L.). *Food Funct.*, *6*, 1345-1351.

918 Roussel C, C. C., Wessam G, Le Goff O, Thévenot J, Chalancon S, Alric M, Thevenot-Sergentet D,
919 Leriche F, Van de Wiele T, Livrelli V, Blanquet-Diot S. . (2016). Increased EHEC survival
920 and virulence gene expression indicate an enhanced pathogenesis upon simulated
921 infant gastrointestinal conditions. *Pediatric Research*, *Accepted 17.5.2016*.

922 Russell, T. L., Berardi, R. R., Barnett, J. L., Dermentzoglou, L. C., Jarvenpaa, K. M., Schmaltz, S. P.,
923 & Dressman, J. B. (1993). UPPER GASTROINTESTINAL PH IN 79 HEALTHY, ELDERLY,
924 NORTH-AMERICAN MEN AND WOMEN. *Pharmaceutical Research*, *10*, 187-196.

925 Salles, N. (2007). Basic mechanisms of the aging gastrointestinal tract. *Digestive Diseases*, *25*,
926 112-117.

927 Sams, L., Paume, J., Giallo, J., & Carriere, F. (2016). Relevant pH and lipase for in vitro models of
928 gastric digestion. *Food & Function*, *7*, 30-45.

929 Sarkar, A., Goh, K. K. T., & Singh, H. (2009). Colloidal stability and interactions of milk-protein-
930 stabilized emulsions in an artificial saliva. *Food Hydrocolloids*, *23*, 1270-1278.

931 Sarkar, A., Goh, K. K. T., & Singh, H. (2010). Properties of oil-in-water emulsions stabilized by
932 beta-lactoglobulin in simulated gastric fluid as influenced by ionic strength and presence
933 of mucin. *Food Hydrocolloids*, *24*, 534-541.

934 Sarles, J., Moreau, H., & Verger, R. (1992). Human gastric lipase: ontogeny and variations in
935 children. *Acta Paediatrica*, *81*, 511-513.

936 Schlamowitz, M., & Peterson, L. U. (1959). Studies on the optimum pH for the action of pepsin
937 on " native" and denatured bovine serum albumin and bovine hemoglobin. *Journal of
938 Biological Chemistry*, *234*, 3137-3145.

939 Seeley, R. R., Stephens, T. D., & Tate, P. (1992). *ANATOMY AND PHYSIOLOGY*.

940 Sensoy, I. (2014). A Review on the Relationship Between Food Structure, Processing, and
941 Bioavailability. *Critical Reviews in Food Science and Nutrition*, *54*, 902-909.

942 Sevenhuysen, G. P., Holodinsky, C., & Dawes, C. (1984). Development of salivary alpha-amylase
943 in infants from birth to 5 months. *The American journal of clinical nutrition*, *39*, 584-588.

944 Shani-Levi, C., Levi-Tal, S., & Lesmes, U. (2013). Comparative performance of milk proteins and
945 their emulsions under dynamic in_vitro adult and infant gastric digestion. *Food*
946 *Hydrocolloids*, *32*, 349-357.

947 Shern, R. J., Fox, P. C., & Li, S. H. (1993). Influence of age on the secretory rates of the human
948 minor salivary glands and whole saliva. *Archives of Oral Biology*, *38*, 755-761.

949 Singh, H., & Ye, A. Q. (2013). Structural and biochemical factors affecting the digestion of
950 protein-stabilized emulsions. *Current Opinion in Colloid & Interface Science*, *18*, 360-370.

951 Tharakan, A., Norton, I. T., Fryer, P. J., & Bakalis, S. (2010). Mass Transfer and Nutrient
952 Absorption in a Simulated Model of Small Intestine. *Journal of Food Science*, *75*, E339-
953 E346.

954 Tortora, G. J., & Derrickson, B. (2011). *Principles of Anatomy and Physiology* (13th ed. Vol. 2).
955 Hoboken: Wiley and Sons Inc.

956 Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007).
957 The Human Microbiome Project. *Nature*, *449*, 804-810.

958 Ulleberg, E., Comi, I., Holm, H., Herud, E., Jacobsen, M., & Vegarud, G. (2011). Human
959 Gastrointestinal Juices Intended for Use in In Vitro Digestion Models. *Food Digestion*, *2*,
960 52-61.

961 UN. (2013). World Population Ageing 2013. In: United Nations.

962 van Vliet, T., van Aken, G. A., de Jongh, H. H. J., & Hamer, R. J. (2009). Colloidal aspects of
963 texture perception. *Advances in Colloid and Interface Science*, *150*, 27-40.

964 Vellas, B., Balas, D., Moreau, J., Bouisson, M., Senegasbalas, F., Guidet, M., & Ribet, A. (1988).
965 Exocrine pancreatic-secretion in the elderly. *International Journal of Pancreatology*, *3*,
966 497-502.

967 Versantvoort, C. H. M., Oomen, A. G., Van de Kamp, E., Rompelberg, C. J. M., & Sips, A. (2005).
968 Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins
969 from food. *Food and Chemical Toxicology*, *43*, 31-40.

970 Versantvoort, C. H. M., Van de Kamp, E. and Rompelberg, C.J.M. (2004). Development and
971 applicability of an in vitro digestion model in assessing the bioaccessibility of contaminants from
972 food. In. Bilthoven, The Netherlands: National Institute for Public Health and the
973 Environment.

974 Vingerhoeds, M. H., Silletti, E., de Groot, J., Schipper, R. G., & van Aken, G. A. (2009). Relating
975 the effect of saliva-induced emulsion flocculation on rheological properties and
976 retention on the tongue surface with sensory perception. *Food Hydrocolloids*, *23*, 773-
977 785.

978 Vors, C., Capolino, P., Guerin, C., Meugnier, E., Pesenti, S., Chauvin, M. A., Monteil, J., Peretti, N.,
979 Cansell, M., Carriere, F., & Michalski, M. C. (2012). Coupling in vitro gastrointestinal
980 lipolysis and Caco-2 cell cultures for testing the absorption of different food emulsions.
981 *Food & Function*, *3*, 537-546.

982 Wada, Y., & Loennerdal, B. (2014). Effects of Different Industrial Heating Processes of Milk on
983 Site-Specific Protein Modifications and Their Relationship to in Vitro and in Vivo
984 Digestibility. *Journal of Agricultural and Food Chemistry*, *62*, 4175-4185.

985 Wada, Y., & Loennerdal, B. (2015). Bioactive peptides released from in vitro digestion of human
986 milk with or without pasteurization. *Pediatric Research*, *77*, 546-553.

987 Wang, G., Agenor, K., Pizot, J., Kotler, D. P., Harel, Y., Van Der Schueren, B. J., Quercia, I.,
988 McGinty, J., & Laferrere, B. (2012). Accelerated Gastric Emptying but No Carbohydrate
989 Malabsorption 1 Year After Gastric Bypass Surgery (GBP). *Obesity Surgery*, *22*, 1263-
990 1267.

991 Yoo, J. Y., & Chen, X. D. (2006). GIT Physicochemical Modeling - A Critical Review. *International*
992 *Journal of Food Engineering*, 2.
993 Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador,
994 D., Avnit-Sagi, T., Lotan-Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G.,
995 Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalova, L., Pevsner-Fischer, M.,
996 Bikovsky, R., Halpern, Z., Elinav, E., & Segal, E. (2015). Personalized Nutrition by
997 Prediction of Glycemic Responses. *Cell*, 163, 1079-1094.

998